企業概要
Nkarta, Inc. (NKTX) is a clinical-stage biopharmaceutical firm dedicated to the development and commercialization of natural killer cell therapies designed to treat cancer and autoimmune diseases. The company operates within the broader healthcare sector, specifically focusing on the biotechnology industry, where it leverages proprietary cell-based technologies to advance therapeutic candidates. As of the latest reporting period, the entity employs 108 individuals and maintains a total market capitalization of $165.39M. The current annual revenue is not disclosed in the available financial data, and the absence of a specific revenue figure alongside the relatively small market cap indicates that the company is likely in a pre-revenue or early-stage commercialization phase, typical for clinical-stage biotechnology firms. This valuation scale suggests the company is currently priced based on its pipeline potential and asset value rather than established cash flow generation, reflecting the high-risk, high-reward profile inherent in the biotechnology sector.
財務健全性
The company's financial statements reveal a net income of $-104,084,000 and an EBITDA of $-106,645,000 over the trailing twelve months, while revenue is not reported in the available data. The substantial gap between the reported net income and EBITDA, both of which are negative, highlights a significant cost structure driven by research and development expenses common in the clinical-stage biotechnology sector. Free cash flow stands at $-53,593,752, indicating that the company is consuming cash to fund its operations and development programs rather than generating liquidity from business activities. Despite the negative free cash flow, the company holds a cash balance of $276.28M, which provides a substantial liquidity buffer against its current debt obligations of $76.42M. The balance sheet shows a debt-to-equity ratio of 24.47, suggesting a leveraged capital structure that relies heavily on equity financing relative to its debt load. The current ratio is recorded at 12.69, a figure that indicates a very strong short-term liquidity position, as the company's current assets significantly exceed its current liabilities. Return on Equity is -28.9% and Return on Assets is -16.0%, metrics that reveal that management is currently generating negative returns on the capital invested, a standard characteristic for growth-stage biotechnology companies focused on pipeline expansion rather than profitability.
バリュエーション評価
The trailing P/E ratio is listed as N/A due to the lack of net income, while the forward P/E is reported at -1.30. The negative forward P/E ratio implies that analysts or the market expects the company to remain unprofitable for the foreseeable future, which is consistent with its clinical-stage development status. The price-to-book ratio is 0.53, indicating that the market is valuing the company at less than half of its book value, suggesting a discount relative to its net asset position. The price-to-sales ratio is not available in the provided data, and the EV/EBITDA stands at 0.32, a metric that suggests a valuation based on enterprise value relative to earnings before interest, taxes, depreciation, and amortization is extremely low, often seen in distressed or high-growth unprofitable firms. The 52-week high for the stock is $2.81 and the low is $1.42, placing the current trading range within a specific volatility band. The beta value is 0.67, which indicates that the stock price volatility is historically lower than that of the broader market, suggesting less sensitivity to general market movements compared to larger-cap equities.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A in the available facts, preventing a direct calculation of growth rates. Consequently, it is not possible to determine whether earnings are growing faster or slower than revenue based on the provided data, as no growth percentages are available for analysis. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. This lack of dividend distribution implies that the company retains all available earnings, if any, and reinvests its resources entirely into research and development activities to advance its clinical pipeline. The overall growth and income profile of Nkarta, Inc. is characterized by a focus on capital appreciation through pipeline milestones rather than current income generation or dividend yield, typical for clinical-stage biopharmaceutical companies.